Effect of YAP1-inhibition in Surgical Wounds.

Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-55
SponsorJöri Pünchera

About this trial

When we get injured, our body naturally tries to heal. In adults, this healing often leads to scars - thick, stiff tissue known as fibrotic tissue. Unlike normal tissue, fibrotic tissue doesn't function properly and can cause serious health problems, depending on the affected organ. Once it forms, fibrosis is usually permanent.

A good example of the fibrosis process is the healing of our skin: after a cut or surgery, the resulting scar is a type of fibrosis. Special cells called fibroblasts are key players in this process.

Our study looks at a drug called verteporfin, which is already approved both in Europe and the U.S. Previous research on mice and human cells suggests it can reduce or even prevent fibrosis.

We are now testing, clinically, histologically and by scRNA-seq, whether injecting verteporfin into the skin during wound healing, specifically after surgical procedures, can prevent thick, rigid scars from forming. Since the skin is easy to observe and sample, it offers a great model for studying this.

Will verteporfin have an impact on how surgical wounds heal? That's what we aim to find out.

Eligibility criteria

Qualifiers

Willing and able to provide informed consent as documented by signature

Age is >/= 18 years and < 56 years (differently said: starting from the 18th birthday to completion of their 55 years)

Indication for a safety margin excision (5 mm laterally) due to melanoma in situ or severe dysplastic nevi previously completely excised

Length of initial scar from 15 mm to 50 mm

Disqualifiers

Clinical adenopathy (cervical, axillar, inguinal) defined as a lymph node of more than 1 cm diameter

Melanoma in situ of lentigo maligna or acral lentiginous type

Head and neck location

Diameter of initial lesion above or equal to 3 cm

Trial design

Treatments tested in this trial

  • NaCl (placebo)
  • Verteporfin Injection

Treatment groups

24 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Jöri Pünchera

Lead sponsor

University Hospital, Geneva

Sponsor institution

University of Geneva, Switzerland

Collaborator

University Hospital, Geneva

Collaborator